A Major Shareholder at Integra Lifesciences is Exercising Options

By Carrie Williams

Today, a Major Shareholder at Integra Lifesciences, Richard Caruso, exercised options of Integra Lifesciences for $1.76M.

Following Richard Caruso’s last IART Sell transaction on February 11, 2016, the stock climbed by 27.1%. In addition to Richard Caruso, 3 other IART executives reported Sell trades in the last month.

Based on Integra Lifesciences’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $369 million and quarterly net profit of $44.36 million. In comparison, last year the company earned revenue of $256 million and had a net profit of $28.25 million. The company has a one-year high of $56.42 and a one-year low of $40.51. IART’s market cap is $4.3B and the company has a P/E ratio of 66.89.

Based on 8 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $56, reflecting a -0.4% downside.

The insider sentiment on Integra Lifesciences has been negative according to 73 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Richard Caruso’s trades have generated a 24.0% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Specialty Surgical Solutions, and Orthopedics & Tissue Technologies segments.